In a clinical trial conducted by Rosell in 2017, the combination of the EGFR inhibitor erlotinib and the VEGFR inhibitor bevacizumab led to an increase in survival in individuals having advanced NSCLC, probably due to the synergistic effects of blocking both the EGF and VEGF pro-angiogenic pathways [53]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.